Ministerio de Industria, Turismo y Comercio LogoMinisterior
 

Alerta

Resultados 914 results.
LastUpdate Updated on 03/04/2026 [07:05:00]
pdfxls
Publicaciones de solicitudes de patente de los últimos 60 días/Applications published in the last 60 days
previousPage Results 450 to 475 of 914 nextPage  

METHODS FOR TREATING NETOSIS AND NEUTROPHIL ACTIVATION

Publication No.:  US20260077028A1 19/03/2026
Applicant: 
TRUSTEES OF BOSTON UNIV [US]
TRUSTEES OF BOSTON UNIVERSITY
US_20260077028_A1

Absstract of: US20260077028A1

Described herein are methods and compositions relating to methods of inhibiting neutrophils, e.g., inhibiting NET release or NETosis, by means of a DEspR inhibitor, e.g., an anti-DEspR antibody reagent. In some embodiments, the methods can relate to the treatment of a disease, e.g., cancer or a disease wherein neutrophils; NETs; or NETosing or NETting neutrophils contribute to pathogenesis, chronicity, or worsening of disease. In some embodiments, the DEspR inhibitor can be a bi-specific reagent or an antibody-drug conjugate.

LIPID-POLYMER CONJUGATES AND LIPID NANOPARTICLES INCORPORATING THE SAME

Publication No.:  WO2026060137A1 19/03/2026
Applicant: 
THE UNIV OF NORTH CAROLINA AT CHAPEL HILL [US]
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
WO_2026060137_A1

Absstract of: WO2026060137A1

Lipid-polymer conjugates and associated lipid nanoparticles are described herein. Such conjugates can comprise polyoxazolines and/or poly oxazines, thereby obviating the use of PEG-based treatments.

LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS AND METHODS OF USE THEREOF

Nº publicación: US20260077038A1 19/03/2026

Applicant:

AKAGERA MEDICINES INC [US]
Akagera Medicines, Inc

US_20260077038_A1

Absstract of: US20260077038A1

The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Anionic phospholipids, including phosphatidylserine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. The further incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation demonstrated high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Finally, the use of an ammonium salt of phosphatidylserine allows for the efficient production of PS-targeted LNPs.

traducir